• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Oncology

Trifluridine–Tipiracil and Bevacizumab Improves Survival in Metastatic Pretreated Colorectal Cancer

byDaniel GoldshteinandSze Wah Samuel Chan
May 15, 2023
in Chronic Disease, Oncology
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. The median overall survival was 10.8 months in the combination group (FTD–TPI + bevacizumab) and 7.5 months in the FTD–TPI alone group, with HR 0.61.

2. The most common adverse events in both groups included neutropenia, nausea, and anemia.

Evidence Rating Level: 1 (Excellent)

Study Rundown: Trifluridine-tipiracil (cytotoxic nucleic acid analogue) is commonly used for refractory disease in patients with metastatic colorectal cancer. Adding a VEGF inhibitor (inhibition of angiogenesis) such as bevacizumab to such patients is thought to be an effective strategy. This phase 3 study continued to build on previous studies that investigated a combination of trifluridine-tipiracil (FTD-TPI) and bevacizumab. The primary end point was overall survival (OS) and secondary endpoints included progression-free survival (PFS), objective response rate (ORR), quality of life (QoL), and safety. The median OS was 10.8 months in the combination group and 7.5 months in the FTD–TPI group, with HR 0.61. Median PFS was 5.6 months in the combination group and 2.4 months in the FTD–TPI group, and an HR of 0.44. ORR was seen in 6.1% of the combination group, and in 1.2% of the FTD–TPI group. Differences in adverse events between arms included hypertension (10.2% in the combination group vs 2.0% in the FTD–TPI group), nausea (37.0% vs 27.2%), and neutropenia (62.2% vs 51.2%). The median time to worsening ECOG from 0-1 to 2+ was 9.3 months in the combination group and 6.3 months in the FTD–TPI group with HR 0.54. The strengths of this paper included its randomized two-arm methodology and large sample size, and the limitations included short follow-up time. Overall the combination of FTD–TPI plus bevacizumab showed improved efficacy compared to FTD–TPI alone in patients with resistant metastatic colorectal cancer.

Click to read the study in NEJM

Click to read an accompanying editorial in NEJM

RELATED REPORTS

Integrated Clinical-Molecular Classification of Colorectal Liver Metastases

Induction Therapy for Patients with Metastatic Colorectal Cancer and Liver Metastases

#VisualAbstract: Trifluridine-Tipiracil and Bevacizumab in Refractory Metastatic Colorectal Cancer

Relevant Reading: Combination of TAS-102 and bevacizumab as third-line treatment for metastatic colorectal cancer: TAS-CC3 study

In-Depth [randomized controlled trial]: This randomized, international, phase 3 trial investigated the combination of trifluridine-tipiracil alone (246 patients) vs trifluridine-tipiracil and bevacizumab (246) in patients with histologically confirmed advanced unresectable adenocarcinoma of the colon or rectum who have progressed on past treatments. 69% of patients have RAS mutations. The median duration of treatment was 5.0 months in the combination group by 2.1 months in the FTD-TPI group with median dose intensities being around 88% and 90% respectively. By the end of the study, 13.0% of patients in the combination group and 1.6% of patients in the FTD-TPI group were continuing to receive treatment. The median OS was 10.8 months (95%CI, 9.4 to 11.8) in the combination group and 7.5 months (95%CI, 6.3 to 8.6) in the FTD–TPI group, with HR 0.61 (95%CI, 0.49 to 0.77, p<0.001).  6-month OS was 77% in the combination group and 61% in the FTD–TPI group, with 12-month OS 43% and 30%, respectively. Median PFS was 5.6 months (95%CI, 4.5 to 5.9) in the combination group and 2.4 months (95%CI, 2.1 to 3.2) in the FTD–TPI group, with HR 0.44 (95%CI, 0.36 to 0.54, p<0.001). The superiority of FTD–TPI plus bevacizumab was observed in all subgroups examined. ORR was seen in 6.1% of the combination group (95%CI, 3.5 to 9.9), and in 1.2% of the FTD–TPI group (95%CI, 0.3 to 3.5). With regards to safety, adverse events (grade ≥3) occurred in 72.4% of the combination group and 69.5% of the FTD–TPI group, with the most common adverse events being neutropenia, nausea, and anemia. Differences in adverse events between arms included hypertension (10.2% in the combination group vs 2.0% in the FTD–TPI group), nausea (37.0% vs 27.2%), and neutropenia (62.2% vs 51.2%). Median time to worsening ECOG from 0-1 to 2+ was 9.3 months (95%CI, 8.3 to 10.6) in the combination group and 6.3 months (95%CI, 5.6 to 7.2) in the FTD–TPI group with HR 0.54 (95%CI, 0.43 to 0.67). Overall the combination of FTD–TPI plus bevacizumab showed improved efficacy compared to FTD–TPI alone in patients with resistant metastatic colorectal cancer.

Image: PD

©2023 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: advanced colorectal cancerTAS-102trifluridine-tipiracil
Previous Post

Temporary interruption of endocrine therapy in women with endocrine-responsive breast cancer did not affect cancer outcomes

Next Post

SMiLE Randomized Trial Supports Incorporating Mindfulness and Self-Compassion Training into the Treatment Plan for Adult Patients with Atopic Dermatitis

RelatedReports

CD45 T cell and macrophage infiltration characteristic of COVID-19 related lung injury
Oncology

Integrated Clinical-Molecular Classification of Colorectal Liver Metastases

August 7, 2023
Resection of colorectal liver metastases may improve cost and longevity
Oncology

Induction Therapy for Patients with Metastatic Colorectal Cancer and Liver Metastases

July 3, 2023
#VisualAbstract: Trifluridine-Tipiracil and Bevacizumab in Refractory Metastatic Colorectal Cancer
StudyGraphics

#VisualAbstract: Trifluridine-Tipiracil and Bevacizumab in Refractory Metastatic Colorectal Cancer

January 29, 2024
Quick Take: Diagnostic Yield of One-Time Colonoscopy vs One-Time Flexible Sigmoidoscopy vs Multiple Rounds of Mailed Fecal Immunohistochemical Tests in Colorectal Cancer Screening
Oncology

Adagrasib provides antitumour activity against KRAS G12C mutant metastatic colorectal cancer both as monotherapy and in combination with cetuximab

January 16, 2023
Next Post
Topical pimecrolimus use for atopic dermatitis not linked to malignancy

SMiLE Randomized Trial Supports Incorporating Mindfulness and Self-Compassion Training into the Treatment Plan for Adult Patients with Atopic Dermatitis

Quick Take: Dual-Energy Computed Tomography Detection of Cardiovascular Monosodium Urate Deposits in Patients With Gout

Price changes in colchicine have changed practice management for gout

Vegetarian diet may lower incidence of colorectal cancer

Children in UK nurseries are willing to eat vegetables offered during breakfast

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Ablation may reduce stroke risk, death, heart failure hospitalization in patients with atrial fibrillation
  • Minimally invasive surgery is beneficial for epithelial ovarian cancer 
  • #VisualAbstract: Tarlatamab Improves Survival in Small-Cell Lung Cancer after Platinum-Based Chemotherapy
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
No Result
View All Result

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.